Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Monthly Archives: July 2024

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Makes Management Announcement, Plans for Strategic Growth

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is preparing for growth by executing a strategic growth plan. A key element of the plan includes expanding the company’s management team to enable efficient handling of a greater … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures FDA Approval for New Form of Buntanetap

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced receipt of approval from the U.S. Food and Drug Administration (“FDA”) to transition to … Continue reading

Posted in Small Cap News | Leave a comment

MissionIRNewsBreaks – Reunion Gold (TSX.V: RGD) (OTCQX: RGDFF) Announces Completion of Business Combination with G Mining Ventures

Reunion Gold (TSX.V: RGD) (OTCQX: RGDFF), a leading gold explorer in the Guiana Shield, has completed its business combination with G Mining Ventures Corp. (TSX: GMIN) (OTCQX: GMINF). The business combination was completed through a court-approved plan of arrangement under … Continue reading

Posted in Reunion Gold Corp. RGDFF | Leave a comment

MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Obtains Notice of Allowance for Key Trademark Identified as ‘Integral’ to Platform Technology

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”). According to the announcement, the notice means that the USPTO anticipates granting the trademark registration covering … Continue reading

Posted in Nutriband Inc. NTRB | Leave a comment

MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Successful Preclinical Results In-Vivo Proof-of-Concept Psoriatic Human Skin Model Study

Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is reporting recent study results. According to the announcement, … Continue reading

Posted in Scinai Immunotherapeutics Ltd. SCNI | Leave a comment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Replicate Results from First GLP-1 Study Following CRO Contract Award for 12-Week Chronic Human Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the hiring of a contract research organization (“CRO”) that will be responsible for overseeing the execution of the company’s upcoming chronic human study, GLP-1-H24-4. This 12-week study … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Correlate Energy Corp. (CIPI) Expanding Solutions to Significant Untapped Market

Correlate (OTCQB: CIPI), a tech-enabled development, finance and fulfillment platform for distributed energy solutions across North America, is strategically working with partners to help clients facilitate green energy transition and improvements. “Correlate Energy is expanding its renewable energy adoption services … Continue reading

Posted in Correlate Infrastructure Partners Inc. CIPI | Leave a comment

MissionIRNewsBreaks – McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) Positioned as Standout Opportunity for Investors

McEwen Mining’s (NYSE: MUX) (TSX: MUX) share price has shown a remarkable gain of 62.1% over the last 12 weeks, indicating strong momentum and robust performance in the market. “This trend of sustained positive momentum over time is a key … Continue reading

Posted in McEwen Mining Inc. MUX | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Significant Improvements from INM-089 in AMD, Validates INM-901 as Potential AD Treatment

InMed (NASDAQ: INM) is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. The company recently released several critical updates regarding its INM-089 therapy treating dry Age-related Macular Degeneration … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks – SuperCom Ltd. (NASDAQ: SPCB) Continues ‘Strong Collaboration’ with New $2.9M Orders from European Governments

SuperCom Ltd. (NASDAQ: SPCB), a global provider of secure solutions for the e-Government, IoT, and cybersecurity sectors, today announced the receipt of new orders from European governments. These orders are valued at $2.9 million and are expected to be delivered … Continue reading

Posted in SuperCom Ltd. SPCB | Leave a comment